Developed specifically to avoid the thrombocytopenia associated with BCLXL inhibition, venetoclax exhibits selectivity for BCL2 over BCLXL (Kd <0.01 nM versus 48 nM, respectively), kills cells in a BAX/BAK-dependent manner, and spares platelets11. This evidence concerns the gene BCL2L1 and Thrombocytopenia.